Inbiomotion

Inbiomotion is dedicated to the development and commercialization of a biomarker that predicts metastasis, with the aim of enhancing the quality of life for breast cancer patients through personalized adjuvant treatment. Established in 2010 as a spin-off from IRB Barcelona and ICREA, the company has created a diagnostic assay based on a highly selective single-gene biomarker. This biomarker has shown promise in identifying early-stage breast cancer patients who are likely to benefit from bisphosphonate adjuvant treatment, potentially improving their overall survival and reducing the risk of invasive disease. Additionally, the biomarker can predict the likelihood of metastases relapse from primary tumors at an early stage, positioning Inbiomotion to advance clinical practices in personalized medicine for breast cancer care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.